Kirby McInerney LLP reminds Erasca, Inc. investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. The lawsuit, filed on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026, alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate, ERAS-0015, including improper comparisons to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose patent and trade secret risks. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and trade secret misappropriation, causing shares to fall 11% from $21.49 to $19.15. A subsequent disclosure of a patient death in a Phase 1 trial and limitations on cross-study comparisons sent shares down an additional 48% to $9.90. Investors who purchased Erasca securities may contact the firm to discuss their rights.
Erasca IncLawsuit alleges false statements about ERAS-0015, patent infringement claims, and patient death, causing stock drops.
Revolution Medicines IncRevMed's patent infringement and trade secret claims against Erasca strengthen its competitive position.